
    
      Primary Objectives

      The primary objectives of this trial are to:

        1. Determine the efficacy of an aggressive treatment protocol in eradicating persistent
           MRSA infection in individuals with CF.

        2. Determine the safety of an aggressive treatment protocol in eradicating persistent MRSA
           infection in individuals with CF.

      Secondary Objectives

      The secondary objectives of this trial are to:

        1. Determine the efficacy of an aggressive treatment protocol in improving Forced
           Expiratory Volume (FEV)1, time to exacerbation, and quality of life in individuals with
           CF and persistent MRSA infection.

        2. Determine if there is benefit to adding nebulized vancomycin to an aggressive oral
           antibiotic treatment protocol in eradicating persistent MRSA infection in individuals
           with CF.
    
  